

Laboratory Service Report

1-800-533-1710

Patient Name SAMPLEREPORT,FFTAS NORMAL	Patient ID SA00062005	Age 42	Gender M	Order # SA00062005
Ordering Phys CLIENT,CLIENT		·		DOB 11/09/1970
Client Order # SA00062005	Account Information			Report Notes
Collected 09/08/2013 13:00	C7028846-DLMP Rochester 3050 Superior Drive			
Printed 09/10/2013 08:53	Rochester, MN 55901			

Test	Flag Results	Unit	Reference Value	Perform Site*
FLT3 (ITD) and TKD Mutation Assay RECEIVED: 09/09/2013 10:57 REPORTE	ED: 09/09/2013 11:09			
Specimen	Bone Marrow			Y06 2
FLT3 Internal Tandem Dup (ITD)	Not detected		Not Detected	Y06 2
FLT3 TKD Mutation	Not detected		Not Detected	Y06 2
Interpretation				Y06 2

The ITD PCR yielded a PCR product of 327 bp. The FLT3 ITD mutation is an adverse prognostic marker in patients with cytogenetically normal acute myeloid leukemia. A patient without a detectable FLT3 ITD mutation generally has a more favorable prognosis that patients with a FLT3 ITD mutation. The FLT3 ITD mutation status must be considered together with all other clinical, molecular, and cytogenetic markers to determine accurate prognosis.

A patient without a detectable FLT3 TKD mutation generally has a more favorable prognosis than patients with a FLT3 TKD mutation. The FLT3 TKD variant mutation defines a distinct leukemic subgroup of cytogenetically normal acute myeloid leukemia. Accurate prognosis of a patient with this mutation must be determined together with all other clinical, molecular, and cytogenetic markers.
*FLT3 Mutation Testing is performed pursuant to patents licensed from Takara Bio of Otsu, Japan.
The Laboratory of Personalized Molecular Medicine is CLIA certified and CAP accredited to perform high complexity testing.

This test was developed and its performance characteristics determined by the Laboratory for Personalized Molecular Medicine. It has not been cleared or approved by the U.S. Food and Drug Administration. However, such approval is not required for clinical implementation, and test results have been shown to be clinically useful.

* Performing Site:

Y062	Laboratory for Personalized Molecular Medicine 6330 Nancy Ridge Drive, Suite 106 San Diego, CA 92121	Lab Director:	

	Collection Date and Time 09/08/2013 13:00	Report Status Final
Page 1 of 1		** End of Report **